Sun Pharmaceutical Industries Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Sun Pharma reported Q1 FY27 consolidated sales of INR1,51,836 million, up 10.1% year-on-year, with gross margin at 80.5% aided by product mix. India formulations grew 16% and Global Innovative Medicines sales rose 12.8% to USD351 million, while U.S. sales declined 9.7% mainly due to Lenalidomide erosion and added competition. Management discussed progress on the Organon acquisition, which has received Organon shareholder approval and remains on track to close, and provided updates on Leqselvi and Unloxcyt launches.
Sun Pharma reported Q4 FY26 sales of INR 1,45,598 million, up 13.6% year-on-year, with EBITDA margin declining to 27.1% from 28.7% a year earlier due to lower milestone income, seasonality, and higher spending in certain geographies including the US. India formulations grew 14.8% and Global Innovative Medicines sales rose 20.1% to US$354 million, while US sales declined 1.1% as generic competition offset Innovative Medicines growth. Management guided to high single-digit consolidated top-line growth for FY27 and continued progress on the Organon acquisition integration, expected to close in Q4 FY27.